Paper Details

  1. Home
  2. Paper Details

Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety.

Author: AchlerkarRahul Raja, BendalePankaj, ChakrabartiDebasis, ChandilPriya, CherlikarVidya, ChoudhurySumit, DasSasmita, DeshmukhSusheel, DeyRituparna, DineshM B, DubeyRama, GuptaRajeev, HalderDebabrata, HazariAjit, HingoraniChanda, JaniSheetal, JohnManuel, KamdarGulam Ali, KishanpuriaSheetal, KumarAjeet, KumarVidya Bhushan, MajumdarNilay Kumar, MathurManoj Chandra, MishraRajesh, NandaAshok Kumar, PahujaKishore, PandeyAlka, RanaViral G, RatnamP Venkat, RavishankarSiddharth, SaikumarS J, ShahDevang Tilak, ShahKaivan, SharmaNeha, SinghParul, SrivastavaRajat Mohan, TopiwalaPratik, VermaSunil Kumar, WadhwaniSunny

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article highlights the role of netarsudil, a Rho kinase inhibitor, in managing primary open-angle glaucoma (POAG). Netarsudil's unique mechanism of action, which involves reorganizing the extracellular matrix to improve aqueous outflow, provides a valuable alternative for lowering intraocular pressure (IOP).
Paper Details　
Original Abstract of the Article :
Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40-80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications tha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418014/

データ提供：米国国立医学図書館（NLM）

A New Treatment for Open-Angle Glaucoma: Netarsudil Monotherapy

The field of [ophthalmology] faces the challenge of [effectively managing open-angle glaucoma], a leading cause of blindness worldwide. This research investigates the efficacy and safety of [netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients]. The study reveals that [netarsudil, a Rho kinase inhibitor, effectively lowers intraocular pressure (IOP) by reorganizing the extracellular matrix to improve aqueous outflow].

Promising Results for IOP Reduction

The research suggests that [netarsudil monotherapy holds promise as a first-line treatment option for open-angle glaucoma and ocular hypertension in Indian patients], demonstrating its potential to [effectively control IOP and prevent vision loss]. This finding is particularly noteworthy as it [addresses the pressing need for effective and safe treatment options in a population with a high prevalence of glaucoma].

Hope for Glaucoma Patients in India

This study provides valuable insights into the potential benefits of netarsudil for glaucoma patients in India. It reinforces the importance of [conducting research tailored to specific populations to address their unique needs and improve patient outcomes].

Dr. Camel's Conclusion

My journey through the vast desert of scientific knowledge has unearthed countless treasures, but few have shimmered as brightly as this study on netarsudil. It's like a refreshing oasis in the parched landscape of glaucoma treatment, offering a glimmer of hope for millions of individuals facing vision loss. Its potential to effectively control IOP, coupled with its safety profile, makes it a promising addition to the ophthalmologist's toolkit. As a researcher, I'm excited to witness the impact this discovery will have on the lives of glaucoma patients, not just in India but around the world.
Date :
  1. Date Completed 2023-06-19
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37322670

DOI: Digital Object Identifier

PMC10418014

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.